Suprachoroidal Drug Delivery: Clinical Pharmacologic Principles

Abstract

Suprachoroidal drug delivery has emerged as a transformative approach in ocular pharmacotherapy, enabling targeted administration of therapeutics to the posterior segment of the eye. This review explores the scientific and clinical foundations of suprachoroidal drug delivery, examining its pharmacologic principles, disease-specific applications, clinical implications, and future directions. Emphasis is placed on current evidence, mechanisms of drug distribution, and guideline-based recommendations relevant to ophthalmologists and healthcare professionals managing retinal and choroidal disorders.

Introduction

The evolution of ocular drug delivery systems has been driven by the need to overcome anatomical barriers and enhance drug bioavailability at targeted intraocular sites. The suprachoroidal space (SCS) offers a novel, minimally invasive route for delivering pharmacologic agents directly to the chorioretinal tissues, minimizing systemic exposure and anterior segment side effects. As clinical trials and real-world studies proliferate, understanding the clinical pharmacologic principles underpinning suprachoroidal delivery is crucial for optimizing therapeutic outcomes in retinal diseases.

Epidemiology / Disease Burden

Retinal and choroidal diseases, including diabetic macular edema (DME), uveitis, and age-related macular degeneration (AMD), represent leading causes of visual impairment globally. The prevalence of diabetes, aging populations, and the chronic, recurrent nature of posterior segment disorders underscore the need for effective, durable drug delivery strategies. Traditional intravitreal injections, though effective, carry risks such as endophthalmitis, intraocular pressure elevation, and cataract formation, highlighting the demand for alternative routes such as the SCS.

Pathophysiology

The SCS is a potential space between the sclera and choroid, extending circumferentially from the optic nerve to the ciliary body. Drug delivery via the SCS enables direct access to the choroid, retinal pigment epithelium (RPE), and outer retina—structures central to the pathogenesis of many posterior segment diseases. By bypassing inner ocular barriers and leveraging the choroidal vasculature's absorptive capacity, suprachoroidal delivery achieves high local drug concentrations while reducing off-target effects.

Risk Factors

Risk factors influencing the efficacy and safety of suprachoroidal drug delivery include patient-specific anatomical variations, scleral thickness, prior ocular interventions, and underlying systemic or ocular comorbidities. Procedural risks such as globe perforation, SCS hemorrhage, or inadvertent subretinal injection are mitigated by advances in microneedle technology and operator expertise. Patient selection and individualized risk assessment remain integral to optimizing clinical outcomes.

Clinical Features

Clinical indications for suprachoroidal drug delivery primarily involve posterior segment diseases refractory to conventional therapies or those requiring sustained, high-concentration drug exposure at the chorioretinal interface. Patients treated via this route may present with persistent macular edema, recurrent inflammatory episodes, or suboptimal responses to intravitreal injections. Monitoring for local complications—such as transient SCS detachment, increased intraocular pressure, or localized inflammation—is essential during follow-up.

Diagnosis

Precise diagnosis of retinal and choroidal pathology is essential to guide candidate selection for suprachoroidal drug delivery. Multimodal imaging—including spectral-domain optical coherence tomography (OCT), fluorescein and indocyanine green angiography, and ultrasonography—enables detailed assessment of disease activity, SCS anatomy, and therapeutic response. Pre-procedural imaging may also identify anatomic variants or contraindications impacting procedural planning.

Treatment & Management

Suprachoroidal delivery is most commonly employed for corticosteroids, anti-VEGF therapies, and emerging biologics. Using specialized microneedle devices, drugs are injected into the SCS under aseptic conditions. Clinical protocols emphasize patient comfort, local anesthesia, and post-procedural observation. Compared to intravitreal administration, this route may reduce anterior segment exposure, lower complication rates, and enable more sustained therapeutic effects. Treatment regimens are tailored according to disease type, severity, and response to previous interventions.

Recent Advances / Emerging Therapies

Recent advances in suprachoroidal drug delivery include the development of novel sustained-release formulations, gene therapy vectors, and cell-based therapeutics. Randomized controlled trials, such as those evaluating triamcinolone acetonide for uveitic macular edema (e.g., PEACHTREE study), have demonstrated significant visual and anatomic improvements. Ongoing research explores the utility of suprachoroidal anti-VEGF agents, immune modulators, and nanocarriers for targeted drug release. Integration of imaging guidance and robotic-assisted delivery systems promises further enhancements in precision and safety.

Guideline Recommendations

Current guidelines from major ophthalmological societies recognize suprachoroidal delivery as an option for select posterior segment diseases, particularly for patients with recurrent or refractory macular edema and non-infectious uveitis. Recommendations emphasize individualized patient assessment, informed consent regarding procedural risks and benefits, and close post-procedural monitoring. As evidence accrues, guideline updates are anticipated to further delineate indications, contraindications, and best practice protocols.

Conclusion

Suprachoroidal drug delivery represents a significant advancement in ocular pharmacotherapy, offering targeted, sustained, and potentially safer treatments for posterior segment diseases. Continued research, technological innovation, and guideline refinement are expected to expand its clinical utility and impact. For ophthalmologists and healthcare professionals, mastery of the pharmacologic principles and procedural nuances of suprachoroidal delivery is essential to harness its full therapeutic potential and improve patient outcomes.